CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

PR Newswire Pharma
Original article

Aethlon Medical & North Immunology Announce Merger to Advance Novel IL-13 x IL-18 Bispecific Antibody for Atopic Dermatitis

NOR-101Positive
AI Analysis

Summary

Aethlon Medical announced a merger with North Immunology to advance NOR-101, a half-life extended anti-IL-13 x IL-18 bispecific antibody for atopic dermatitis, with an oversubscribed $180 million offering.

Importance:7/10
Sentiment:
0.70
mergeracquisitionbispecific antibodyatopic dermatitisIL-13IL-18
Related Companies
$MDCE

Read the original article

Published by PR Newswire Pharma on September 17, 2026 10:30 AM

Read Original